Haemophilia Trial, Recruiting NCT07414511 Sponsor: University of Washington Condition: Haemophilia
Back to Haemophilia

Haemophilia Trial, Recruiting

NCT07414511
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Pregnant people (to be enrolled during pregnancy):

  • People who are currently pregnant and have not yet reached 37 weeks of pregnancy
  • People who are known to carry, or may carry, a severe form of the genetic condition hemophilia A
  • People who are pregnant with at least one baby that has a chance of inheriting severe hemophilia A
  • People who are 18 years of age or older
  • People who are able to understand and agree to take part in the study

Pregnant people (to continue in the study before week 38 of pregnancy):

  • People confirmed to carry the genetic change that causes severe hemophilia A
  • People whose baby has been assessed as having a 25% or higher chance of inheriting severe hemophilia A, or whose prenatal testing shows the baby is affected by severe hemophilia A
  • People who have not met any criteria that would require leaving the study

Children (assessed by 8 weeks of age):

  • Babies born to a mother already participating in the study
  • Babies diagnosed with severe hemophilia A, meaning their blood has very low or undetectable levels of a clotting protein called Factor VIII, or they carry a genetic change predicted to cause severe hemophilia A

Blood relatives of the child:

  • Close relatives such as a parent or sibling (first-degree relatives)
  • Extended relatives such as aunts, uncles, grandparents, or half-siblings (second-degree relatives)
  • More distant male or female blood relatives whose information may help researchers better understand hemophilia A and related complications

Who may not be able to join:

Pregnant people:

  • People whose genetic testing shows they do not carry the genetic change for severe hemophilia A
  • People whose prenatal testing shows that no baby in the pregnancy is affected by severe hemophilia A
  • People who have another significant bleeding disorder
  • People taking part in another study where the combined blood draws would go beyond the safety limits set for this study
  • People who plan to give birth outside the United States, or whose child will receive regular ongoing medical care outside the United States
  • People who are currently imprisoned
  • People for whom study documents cannot be translated into their language in time for participation, if they are not fluent in English
  • People the study investigators consider unsuitable for participation for any other reason

Children:

  • Babies who are found not to have severe hemophilia A after testing
  • Babies whose mother or the baby themselves did not have the minimum required samples or information collected before birth, around the time of delivery, or in the newborn period
  • Babies who have another significant bleeding disorder
  • Babies who have a serious immune system condition
  • Babies enrolled in another study where the combined blood draws would exceed the safety limits set for this study
  • Babies the study investigators consider unsuitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jill M Johnsen, MD, University of Washington

Phone: 206 568-2230

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
31 July 2024
Est. completion
1 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Primary Endpoint(s)/Outcome(s)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov